Medimmune Limited

Astrazeneca Ab

Amgen Fremont Inc.

Medlmmune Limited

Gadi Gazit-Bornstein

Xiao-Dong Yang

Susan Ann Cartlidge

David William Tonge

Olivia Raeber

Ian Nevin Foltz

Jaspal Singh Kang

David Charles Blakey

Naomi Laing

Sue Ann Cartlidge

Xiao-Dang Yang

Bruce Alan Keyt

Giorgio Senaldi

Xiaodong Yang

Gerardo Zapata

Laura Taylor

Xiaodong Intradigm Corporation Yang

Binding proteins, such as antibodies directed to IGF-II with cross-reactivity to IGF-I and uses of such antibodies are described. In particular, fully human monoclonal antibodies directed to the IGF-II with cross-reactivity to IGF-I are disclosed. Also discussed are nucleotide sequences encoding, and amino acid sequences comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3.

Binding proteins specific for insulin-like growth factors and uses thereof

Targeted binding agents directed to the antigen PDGFR-alpha and uses of such agents are disclosed herein. More specifically the invention relates to fully human monoclonal antibodies directed to the antigen PDGFR-alpha and uses of these antibodies. Aspects of the invention also relate to hybridomas or other cell lines expressing such antibodies. The described targeted binding agents and antibodies are useful as diagnostics and for the treatment of diseases associated with the activity and/or overexpression of PDGFR-alpha.

Targeted binding agents directed to PDGRF-alpha and uses thereof

Methods of using insulin-like growth factor antibodies to treat tumors

Insulin-like growth factor antibodies and uses thereof

Targeted binding agents directed to PDGFR-alpha and uses thereof

The present invention is related to antibodies directed to the antigen properdin and uses of such antibodies. In particular, in accordance with the present invention, there are provided fully human monoclonal antibodies directed to the antigen properdin. Nucleotide sequences encoding, and polypeptides comprising, heavy and light chain immunoglobulin molecules, particularly sequences corresponding to contiguous heavy and light chain sequences spanning the framework regions and/or complementarity determining regions (CDR's), specifically from FR1 through FR4 or CDR1 through CDR3, are provided. Hybridomas or other cell lines expressing such immunoglobulin molecules and monoclonal antibodies are also provided.

Anti-properdin antibodies, and methods for making and using same

Growing community of inventors

Waltham, MA, United States of America

Gadi Gazit-Bornstein